Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JT001 (VV116) vs Paxlovid for Early Treatment of Mild to Moderate COVID-19
NCT05341609Phase 3Completed
- Sponsor
- Vigonvita Life Sciences
- Start
- Apr 2022
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 3 trial of deuremidevir in coronavirus disease 2019 (COVID-19), sponsored by Vigonvita Life Sciences. Started Apr 2022; status: completed.
02
Drugs
deuremidevir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05341609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05341609.